ModifiedPremera BluecrossPolicy N/A

Nulojix (belatacept) for Adults - Medical Policy

Medical necessity and site-of-service review criteria for use of Nulojix (belatacept) in adults for prevention of kidney transplant rejection, including induction and maintenance therapy, documentation, coding, and evidence considerations. Applies to providers submitting requests for coverage and site-of-service determinations.

Policy Summary

PayerPremera Bluecross

PolicyNulojix (belatacept) for Adults - Medical Policy

Policy CodePolicy N/A

Change TypeMaterial revision and clarifications

Effective DateJun. 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document EBV seropositive status, concurrent immunosuppressants, and clinical justification for any conversion from CNI before approval.

SourceLink

POLICY UPDATE CHANGES

Updated Nulojix (belatacept) length of initial approval from 6 months to 12 months.

Clarified that the Site of Service Medical Necessity criteria does not apply to Alaska fully-insured members; only infusion drug medical necessity applies per Alaska HB 226.

Added note that azathioprine can be used for individuals who have tried and did not tolerate mycophenolate mofetil (MMF).

Clarified that medications listed are subject to the product's FDA dosage and administration prescribing information.

Added an exception to the site-of-service requirements for certain individuals receiving treatment for cytokine release syndrome (CRS).

Clarified that the Site of Service Medical Necessity criteria can apply to injection drugs.

18+minimum age (years)

EBV+EBV serostatus required

J0485

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12 moapproval duration

increasedconversion risk

Alaskastate exception

Coverage Criteria for Nulojix (belatacept)

Initial and maintenance therapy — kidney transplant

Covered when ALL of the following are met for adults receiving a kidney transplant:

Adult kidney transplant recipient: The individual is aged 18 years or olderage >= 18

[[chunk 7]]

EBV serostatus: Documented Epstein–Barr virus (EBV) seropositive test resultEBV seropositive

EBV seronegative or unknown serostatus is contraindicated due to increased risk of post‑transplant lymphoproliferative disorder (PTLD). [[chunk 7]]

Concomitant immunosuppression: Nulojix (belatacept) is prescribed in combination with all of the following: basiliximab (Simulect) for induction, mycophenolate mofetil (MMF) (or azathioprine if MMF not tolerated), and corticosteroidsconcurrent medications documented

Manufacturer‑recommended combination referenced in policy criteria and trial regimens. [[chunk 7]]

Length of approval

Authorization duration and re-authorization:

Approval period: Initial authorization and re‑authorization for Nulojix (belatacept) may be approved for up to 12 months if coverage criteria are met and chart notes demonstrate continued positive clinical response to therapy<= 12 months

Initial approval length updated to 12 months in the 2026 update; re‑authorization may also be up to 12 months per policy. [[chunk 8]][[chunk 31]][[chunk 38]]

Conversion from CNIs

Conversion from CNI-based regimens:

Conversion caution: Conversion from a calcineurin inhibitor (CNI)–based maintenance regimen (e.g., tacrolimus or cyclosporine) to a belatacept‑based regimen increases the risk of acute rejection and is not recommended unless the individual is CNI intolerantclinical justification for conversion (CNI intolerance) documented

Randomized studies showed higher rejection rates during the first year after conversion; prescribing information updated in 2021 to reflect increased rejection risk. [[chunk 18]]

Clinical coverage considerations

Coverage considerations and clinical guidance summarized from evidence and updates

Risk/benefit summary: Belatacept‑based regimens have demonstrated improved renal function (higher cGFR) versus cyclosporine in trials, but safety signals include increased risk of PTLD and infections; weighing renal‑sparing benefits against early acute rejection risk is requiredclinical risk/benefit documented

Evidence reviews and trial data summarized in policy; safety warnings and malignancy/PTLD risks noted. [[chunk 18]]

Use settings: Belatacept may be used for de novo induction/maintenance or maintenance therapy post‑induction when criteria are met

Policy includes both induction and maintenance pathways contingent on the criteria in the coverage sections. [[chunk 7]]

Alternative for MMF intolerance: Azathioprine may be used when mycophenolate mofetil (MMF) has been tried and not tolerateddocumented intolerance to MMF

Site-of-Service and Drug Medical Necessity Interaction

Covered when medical necessity and site-of-service criteria are met per policy; specific clinical criteria and pediatric investigational statements referenced in prior sections.

Site‑of‑Service exception: A site‑of‑service exception may be allowed when there is no outpatient infusion center within 50 miles of the individual’s home and no contracted home infusion agency will travel to the home, or the hospital is the only place offering infusions; certain exceptions exist for specific conditions (e.g., CRS)distance: 50 miles

Site‑of‑service exception definition and 50‑mile threshold appear in policy history and site‑of‑service criteria; Alaska fully‑insured members are excluded from SOS criteria (only infusion drug medical necessity applies). [[chunk 36]][[chunk 3]][[chunk 38]]

Pediatric use: Use of Nulojix in individuals under 18 years of age is considered investigational and is not coveredage < 18

No pediatric studies support safety/efficacy; policy explicitly lists pediatric use as investigational. [[chunk 8]]

Use of Nulojix (belatacept) for prophylaxis of organ rejection in organs other than kidney is considered investigational. This policy applies to medical benefit reviews for outpatient/injection site-of-service determinations and does not apply to members who are currently admitted to an acute hospital setting.

Historically, Nulojix (belatacept) has been designated investigational for pediatric patients because there were no adequate studies to support safety and effectiveness in this population; this policy history note was added in 2017.

Current policy statements continue to treat pediatric use as investigational — Nulojix is covered with criteria for adult kidney transplant recipients but not for pediatric patients due to lack of supporting studies.

Belatacept is contraindicated in individuals who are Epstein-Barr virus (EBV) seronegative or whose EBV serostatus is unknown because of a particularly increased risk of post‑transplant lymphoproliferative disorder (PTLD); requests for Nulojix will be denied in these circumstances.

Conversion of stable kidney transplant recipients from a calcineurin inhibitor (CNI)‑based maintenance regimen to a belatacept‑based regimen is not routinely recommended. Evidence and prescribing information note that conversion increases the risk of acute rejection; conversion should only be considered when there is documented CNI intolerance.

Per policy history and prior reviews, use of Nulojix in pediatric patients remains listed as investigational and is not covered because of insufficient pediatric safety and efficacy data.

Kidney Transplant Candidate Criteria

Kidney transplant candidate criteria

Kidney transplant recipients:

Age and serostatus: Adult (>= 18 years) kidney transplant recipients who are EBV seropositiveage >= 18; EBV seropositive

Policy criteria require adult age and documented EBV seropositivity; EBV seronegative or unknown serostatus is contraindicated. [[chunk 7]]

Required concomitant regimen: Use only in combination with basiliximab induction (when applicable), MMF (or azathioprine if MMF intolerant), and corticosteroids — concurrent medications must be documented in the medical recordconcurrent meds documented

Concomitant immunosuppression regimen is specified in the policy criteria and must be documented. [[chunk 7]] [[chunk 3]]

Contraindications and Warnings

Nulojix (belatacept) coverage for kidney transplant is limited to adult recipients who are EBV seropositive; the policy specifically notes that use in liver transplant individuals is not recommended by the manufacturer due to increased risk of graft loss and death.

Additional contraindications and prescribing warnings include prior T‑cell depleting therapies and other strong immunosuppressive exposures described in the product information; these increase the risk of opportunistic infections, malignancies (including PTLD), and rare events such as progressive multifocal leukoencephalopathy (PML). Site‑of‑service and documentation requirements also apply (for example, SOS review for ages 13+ and exclusions for inpatients).

Clinical and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required for outpatient conversion to belatacept and for initiation when applicable. Initial authorizations are typically requested for a defined duration (document requested duration); prior authorization must specify the requested authorization length and include supporting clinical documentation.

Provider must request Initial authorization duration and specify Prior authorization duration in the request.
Authorization length should align with prescribing information and documented clinical need.

Documentation Required

Documentation must be present in the medical record and submitted with the authorization request. Required clinical documentation includes: transplant type (kidney, multi-organ), EBV serostatus, current immunosuppressive regimen and any intolerance or contraindications (including evidence supporting CNI or MMF intolerance), operative and hospital discharge summaries if applicable, and a focused H&P demonstrating indication for conversion or initiation.

Prior Authorization, Prescribing and Provider Responsibilities

Prior Authorization

Prior authorization required; bill with J0485

Obtain prior authorization for belatacept; bill using HCPCS code J0485 (Injection, belatacept, 1 mg).

Submit prior authorization request before therapy initiation.
Use HCPCS J0485 to bill belatacept per unit (1 mg).

Prior Authorization

Initial authorization length: up to 12 months

Initial authorizations for Nulojix (belatacept) may be approved for up to 12 months; update reflects change from prior 6‑month initial approvals to 12 months.

Request initial approval duration up to 12 months on prior authorization submission.

Prior Authorization

Authorization duration — align with FDA dosing

Initial prior authorizations are for up to 12 months; authorization decisions should consider the product's FDA dosing and administration information.

Billing and Coding

HCPCS codesHCPCSCovered

J0485

Injection, belatacept (Nulojix), 1 mg

HCPCS codes historically listed/modifiedHCPCS

J0485	Belatacept (Nulojix), per 1 mg
C9286	Previously listed code deleted effective 12/31/12
J3490	Removed (non-specific) per policy history
J3590	Removed (non-specific) per policy history
J7599	Removed (non-specific) per policy history

HCPCS code history and statusHCPCS

J0485	Specific HCPCS code J0485 added (new code 1/1/13)
C9286	C9286 deleted effective 12/31/12
J3490	J3490 removed (non-specific) per 08/11/15
J3590	J3590 removed (non-specific) per 08/11/15
J7599	J7599 removed (non-specific) per 08/11/15

Site-of-service age threshold

Site-of-service age threshold>= 13 years

RationaleSite-of-service review is limited to individuals aged 13 years and older due to pediatric-specific infusion needs

Applies toSite-of-service medical necessity reviews (hospital outpatient, infusion center, physician office, home)

Site of Service distance threshold

Distance threshold for SOS exception50 miles

Exception criteriaNo outpatient infusion center within 50 miles and no contracted home infusion agency will travel

Maintenance and Post-Transplant Coverage

Maintenance immunosuppression with belatacept — continuation allowed if criteria met

Coverage stance for maintenance therapyContinuation of belatacept (Nulojix) for maintenance immunosuppression is allowed when drug-specific coverage criteria are met and chart notes document a positive clinical response

PopulationAdults receiving kidney transplant maintenance therapy

Concomitant therapy requirementUse in combination with basiliximab induction, mycophenolate mofetil (or azathioprine if MMF intolerant), and corticosteroids per policy

Maintenance immunosuppression evidence — improved renal function vs CNI but safety signals (PTLD, infections)

Renal function benefitBelatacept maintenance regimens associated with improved renal function (higher mean cGFR vs CNI at 2–3 years)

Safety signals

Definitions and Terminology

Belatacept (Nulojix) mechanism of action

Mechanism of actionBelatacept inhibits T-lymphocyte proliferation by binding CD80 and CD86 on antigen-presenting cells, blocking CD28 co-stimulation

Cytokine effectsReduces production of interleukin-2 and -4, interferon, and TNFα

Clinical implicationBlocks T-cell co-stimulation to reduce immunologic rejection mediated by activated T lymphocytes

Site of Service (SOS) definition

DefinitionSite of Service (SOS) is the location where the drug is administered (hospital-based outpatient setting, infusion center, physician office, or at home)

Scope of SOS reviewSOS medical necessity criteria applies to medical benefit reviews and, for SOS review, is limited to individuals aged 13 and older

Site and Center Requirements

Note

Site‑of‑Service medical necessity review applies; medically necessary sites defined

Site‑of‑service medical necessity review applies for medical benefit reviews and defines medically necessary sites (physician office, infusion center, home infusion, hospital‑based outpatient); ensure the requested site meets SOS medical necessity criteria.

Confirm intended administration site on the authorization.
For ages ≥13, SOS review will be performed for medical benefit requests.

Note

No transplant center accreditation specification in policy history

Policy history references site‑of‑service and infusion setting requirements but does not specify transplant center accreditation; do not assume accreditation requirements beyond the defined SOS criteria.

Rely on SOS criteria (location and access) rather than transplant center accreditation for authorization decisions.

Background and Clinical Context

Belatacept (Nulojix) is a selective T‑cell co‑stimulation blocker that inhibits T lymphocyte proliferation by binding CD80 and CD86 and blocking CD28 co‑stimulation, reducing production of interleukins and other cytokines. It is indicated as an infused alternative to oral calcineurin inhibitors for prevention of kidney transplant rejection, and trials have demonstrated improved renal function measures versus cyclosporine though with higher early acute rejection rates; the drug carries a boxed warning for increased risk of PTLD, particularly in EBV‑seronegative individuals.

Policy Summary

PayerPremera Bluecross

PolicyNulojix (belatacept) for Adults - Medical Policy

Policy CodePolicy N/A

Change TypeMaterial revision and clarifications

Effective DateJun. 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document EBV seropositive status, concurrent immunosuppressants, and clinical justification for any conversion from CNI before approval.

SourceLink

On This Page

Policy updated in 2023 to add azathioprine as an alternative when MMF intolerance is documented. [[chunk 28]]

Office visit notes containing type of transplant, EBV serostatus, concurrent medication use, and relevant H&P.
Documentation should support site-of-ser — indicate where EBV serology was performed (inpatient vs outpatient lab).
If conversion is due to intolerance, include evidence of intolerance to the current agent (e.g., lab abnormalities, adverse reaction documentation).
If MMF intolerance is claimed and azathioprine is being considered as an alternative, include documentation showing step from MMF to azathioprine and rationale.
Prescribing information and proposed authorization length must be included.

Denial Risk

EBV Serostatus and Conversion Risk

Patients who are EBV seronegative or have unknown EBV serostatus are at increased risk of post-transplant lymphoproliferative disease (PTLD) with belatacept. Conversion to belatacept is contraindicated or carries high risk in EBV-seronegative individuals — prior authorization will be denied without explicit documentation of EBV serostatus and risk assessment.

Include documented EBV serostatus (positive/negative) and date of testing.
If EBV serostatus is negative or unknown, include specialist justification and risk mitigation plan; inpatient initiation is generally excluded without clear inpatient infectious disease/transplant team rationale.

Indicate planned dosing/administration consistent with FDA prescribing information in the request.

Step Therapy

Use with basiliximab, MMF (or azathioprine), and corticosteroids

Nulojix must be used in combination with induction with basiliximab (Simulect) and maintenance with mycophenolate mofetil (MMF) and corticosteroids; azathioprine may be substituted if MMF is not tolerated.

Induction: Simulect (basiliximab).
Maintenance: MMF plus corticosteroids.
If MMF intolerance documented, azathioprine may be used instead.

Step Therapy

Azathioprine acceptable when MMF not tolerated

If the member has documented intolerance to mycophenolate mofetil (MMF), azathioprine may be used as an alternative in the concomitant immunosuppressive regimen.

Include documentation of MMF intolerance when proposing azathioprine.

Step Therapy

Step to azathioprine requires documented MMF intolerance

When requesting azathioprine in place of MMF, include documentation that MMF was tried and not tolerated; the policy explicitly allows azathioprine when MMF intolerance is documented.

Attach prior medication history and adverse event documentation showing MMF intolerance.

Documentation Required

Include office notes, EBV status, meds, and histology

Provide office visit notes that include transplant type, EBV serostatus, current concurrent medications, and histology or other relevant clinical data as applicable to support medical necessity for belatacept.

Office notes must list transplant type and EBV serostatus.
List all concurrent immunosuppressive agents and any relevant histology results.

Billing Rule

Follow FDA dosing; initial authorization up to 12 months

Medications must be administered consistent with the product's FDA dosing and administration; initial authorizations have been updated to allow approvals up to 12 months.

Document planned dosing consistent with FDA prescribing information.
Request duration up to 12 months on authorization forms.

Documentation Required

Document prior infusion access and site‑of‑service exception rationale

When requesting a site‑of‑service exception or a non‑standard infusion location, include documentation of prior infusion access attempts and reasons an outpatient infusion center or home infusion is not feasible.

Document distance to nearest outpatient infusion center and availability of home infusion.
Provide prior infusion history if relevant.

Denial Risk

EBV seropositive required — lack of positive result risks denial

Do not approve belatacept for individuals who are EBV seronegative or whose EBV serostatus is unknown; requests lacking documented EBV seropositivity will be denied because of increased PTLD risk.

Attach EBV serology showing seropositive status to the authorization request.
If EBV status is unknown, obtain and document testing prior to approval.

Denial Risk

Policy does not apply to currently hospitalized members

Requests for Nulojix are not applicable under this policy for members currently admitted to an acute hospital setting; inpatient admissions fall outside the policy's application.

Do not submit authorization requests under this policy for currently hospitalized (acute) members.

Documentation Required

Document counseling on increased rejection risk with conversion

Document that the patient was counseled on the increased risk of acute rejection associated with conversion from a CNI‑based maintenance regimen to belatacept; conversion increases early rejection risk and is not recommended unless CNI intolerance is documented.

Include documentation of counseling and informed consent regarding rejection risk.
Provide clinical justification for conversion (e.g., documented CNI intolerance).

Denial Risk

Site‑of‑service exception requires documented lack of access (≤50‑mile rule)

If requesting a site‑of‑service exception, document lack of reasonable access (e.g., no outpatient infusion center within 50 miles or no contracted home infusion agency); absence of such access documentation may lead to denial of the exception.

Provide address and distance evidence to nearest outpatient infusion center.
Document attempts to secure home infusion services if applicable.

AlternativeHospital is considered medically necessary if it is the only place offering the infusion or injection

Observed safety concerns include increased cases of post-transplant lymphoproliferative disorder (PTLD), tuberculosis, and higher rates of some fungal infections

Conversion riskConversion from CNI-based regimens to belatacept increases early acute rejection risk; conversion not recommended unless CNI intolerance documented

Nulojix infusion therapy — initial approval length updated to 12 months

Initial approval lengthInitial authorization for Nulojix (belatacept) updated to up to 12 months

Re-authorizationRe-authorizations may be approved up to 12 months if criteria are met and chart notes show continued positive clinical response

Policy changeReference to prior 6-month initial approval removed in 2026 update; 12-month initial approval effective per history

Alaska exceptionSOS Medical Necessity criteria does not apply to Alaska fully-insured members; refer only to infusion/injection drug medical necessity criteria

Conversion definition

DefinitionConversion = changing a patient's maintenance immunosuppression from a calcineurin inhibitor (CNI)-based regimen (e.g., cyclosporine or tacrolimus) to a belatacept-based regimen

Risk noteConversion increases risk of acute rejection, particularly during the first year post-conversion

RecommendationConversion is not recommended unless the individual is documented to be CNI intolerant

Site-of-service exception definition (50 miles / home infusion availability)

Exception definitionSite-of-service exception allowed when there is no outpatient infusion center within 50 miles of the individual’s home and no contracted home infusion agency will travel

Alternate conditionHospital is considered medically necessary if it is the only place that offers infusions or injections of the drug

DocumentationDocumentation should support claims of access exception (distance or home infusion availability); lack of documented access may trigger denial